Objectives: We aimed to investigate potential associations between human leukocyte antigen (HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions in patients with multiple sclerosis (MS) treated with natalizumab.
development of anaphylactic/anaphylactoid reactions in patients with MS treated with natalizumab was associated with particular HLA class I and class II alleles.
METHODS Patients and HLA typing. Inclusion criteria were patients with MS treated with natalizumab who developed anaphylactic/anaphylactoid reactions within 2 hours after infusion between the second and eleventh administrations of natalizumab, which motivated natalizumab suspension. Patients fulfilled the clinical criteria for the diagnosis of anaphylaxis promulgated in the World Allergy Organization anaphylaxis guidelines. 8 Patients with MS who did not develop anaphylactic/anaphylactoid reactions during natalizumab infusions were used as controls.
Genomic DNA was extracted from peripheral blood samples using standard methods. HLA genotyping was performed by means of the PCR-SSOP Luminex method using Lifecodes HLA-A, HLA-B, HLA-DRB1, and HLA-DQB typing kits (Immucor Gamma Transplant Diagnostics, Inc., Heppignies,-Belgium) according to the manufacturer's instructions.
Statistical analysis. Statistical analysis was performed by using the SPSS 17.0 package (SPSS Inc., Chicago, IL). Comparisons of groups were analyzed using the x 2 test of a Fisher exact test (when expected values were below 5). To calculate combined odds ratios (ORs) and 95% confidence intervals (CIs), we used the Cochran-MantelHaenszel method implemented in Review Manager RevMan v. 5.0 (The Nordic Cochrane Centre, Copenhagen, Denmark). p values ,0.05 were considered statistically significant. The Der Simonian and Laird random effects model was used according to the results of the tests of heterogeneity. A sensitivity analysis was performed to test the relative influence of each study on the results. Studies were sequentially dropped, and the effect on the change in the overall degree of heterogeneity was determined.
Standard protocol approvals, registrations, and patient consents. The study was approved by the corresponding local ethics committees, and all patients gave their informed consent. RESULTS A total of 119 patients with MS belonging to 3 different cohorts (French, n 5 63; Spanish, n 5 48; German, n 5 8) were included in the study. A summary of demographic and main clinical characteristics of patients with MS who participated in the study is shown in 
In the European population, the frequencies of the HLA-DRB1*15 and HLA-DRB1*13/*14 alleles are 14% each.
Most probably these risk and protective HLA class II alleles conformed ancestral haplotypes with class I alleles, since the HLA-DRB1*13 and HLA-DRB1*14 alleles were frequently accompanied by HLA-A*24, and the HLA-DRB1*15 allele by HLA-A*03 or HLA-B*07 (see tables e-2 and e-3). Nonetheless, the HLA class II alleles remained the best associated markers of DISCUSSION Two types of infusion-related hypersensitivity reactions have been described in patients with MS treated with natalizumab: type I allergic reactions, which usually occur within 2 hours after infusion, 1 and type III hypersensitivity reactions, which typically develop during several days. 9 Type I hypersensitivity reactions include serious systemic anaphylactic/anaphylactoid, with an incidence that has been reported to be near 4% in some observational studies. 3, 6 When these hypersensitivity reactions are present, administration of natalizumab must be discontinued and patients should not be retreated.
Aiming to identify patients at risk for developing anaphylactic/anaphylactoid reactions to natalizumab, we performed HLA typing for class I and class II alleles in patients with MS from 3 different cohorts who were treated with natalizumab. The selection of the HLA region as the main target for genotyping was based on current evidence in the literature demonstrating significant associations between HLA and predisposition to adverse drug reactions. 7 Drug hypersensitivity reactions are supposed to be mediated by inappropriate T-cell activation, and the key proteins implicated in these responses are the HLA molecules. Several models have been proposed to explain the mechanisms whereby small synthetic compounds are recognized by T cells in an HLAdependent manner, including the hapten/prohapten model, the altered peptide repertoire model, and the p-i model (pharmacologic interaction of drugs with immune receptors). 10 Examples of drug-induced hypersensitivity reactions influenced by the HLA are the reactions to the reverse-transcriptase inhibitor abacavir and the xanthine oxidase inhibitor allopurinol, which are mediated by HLA class I alleles, and the reactions to the reverse-transcriptase inhibitor nevirapine and the first-line anticonvulsant carbamazepine, which are mediated by both HLA class I and class II alleles. 7, 10 Patients with MS carrying HLA-DRB1*13 and HLA-DRB1*14 alleles were at higher risk for developing natalizumab-related anaphylactic/anaphylactoid reactions compared to patients without allergic reactions, with an OR of 9 and a PPV of 82%. On the other hand, the HLA-DRB1*15 allele, which is known to be the main genetic risk for MS, had a protective effect on the development of anaphylactic/anaphylactoid reactions, with an OR of 0.2 and a PPV of 81%.
Neutralizing antibodies against natalizumab are usually present in patients having type I hypersensitivity reactions. 11 In our study, 81% of the patients with MS who experienced anaphylactic/anaphylactoid reactions were positive for anti-natalizumab antibodies.
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